2-Mercapto-6-Propylpyrimidin-4-ol 6-丙基-2-巯基-4-羟基嘧啶

CAS 51-52-5 MFCD00006041

化学结构图

51-52-5
SMILES: CCCc1cc(=O)[nH]c(=S)[nH]1

化学属性

Mol. FormulaC7H10N2OS
Mol. Weight170
Density1.24
Melting Point218-220
Solubility1.1 G/L
Flash Point300 °C
Appearance 白色结晶或结晶性粉末, 无臭、味苦,在乙醇中略溶,在水中极微溶解,在氢氧化钠试液或氨试液中溶解。 本品无毒,无麻醉作用,不属易燃易爆品。

别名和识别编码

Chemical Name2-Mercapto-6-Propylpyrimidin-4-ol
Synonym 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo- 2-Mercapto-6-propylpyrimid-4-one Propythiouracil 4-羟基-2-巯基-6-丙基嘧啶 6-Propylthiouracil 6-Propyl-2-thiouracil 2-Mercapto-6-propyl-4-pyrimidone Propilthiouracil Prothiurone 4-Propyl-2-thiouracil Propacil 丙硫氧嘧啶 Propyl-thyracil 2-Thio-4-oxo-6-propyl-1,3-pyri 6-Thio-4-propyluracil 4-PROPYL-2-THIOURACIL 2-Mercapto-4 Prothyran 2,3-dihydro-6-propyl-2-thioxo-4(1h)-pyrimidinon 丙基硫氧嘧啶 2-Thio- Thiuragyl 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione 6-Propil-tiouracile Procasil 6-Propyl-2-thiouracil; 2-Mercapto-6-p Propyl-thiorist Propylthiouracil
MDL NumberMFCD00006041
CAS Number51-52-5
EC Number200-103-2
Beilstein Registry Number130039
PubChem Substance ID87574714
Reaxys-RN130039
Merck Number7869
Chemical Name Translation6-丙基-2-巯基-4-羟基嘧啶
Wiswesser Line NotationT6MYMVJ BUS F3
LabNetwork Molecule IDLN00193141
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Alphabetical Index of Analytical Standards, Analytical Standards, Antibiotics, Chemical Structure, Chromatography, Clinical Standards, Others, P, PON - PT, 分析/色谱
  • {SNA} Additional Standards, Analytical Standards, Antibiotics Standards,

产品应用

  • 抗甲状腺药。

相关文献及参考

  • Merck: 14,7869 Beilstein: 24,IV,1333
  • Merck: 14,7869

安全信息

Signal word
GHS Symbol
WGK Germany3
Safety Statements
  • S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套;
  • S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时,立即求医(可能时出示标签);
Risk Statements
  • R36/37/38 Irritating to eyes, respiratory system and skin 对眼睛、呼吸系统和皮肤有刺激性
  • R22 Harmful if swallowed 吞咽有害
  • R40 Limited evidence of a carcinogenic effect 有限证据表明其致癌作用
Precautionary statements
  • P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
  • P260 Do not breathe dust/fume/gas/mist/vapours/spray. 不要吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P305+P351+P338
  • P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
  • P281 Use personal protective equipment as required. 使用所需的个人防护装备。
  • P201 Obtain special instructions before use. 使用前获取专门指示。
  • P501 Dispose of contents/container to..… 处理内容物/容器.....
  • P405 Store locked up. 上锁保管。
  • P308+P313
  • P301+P312+P330
  • P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西,喝水或吸烟。
  • P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前,切勿操作。
Hazard statements
  • H302 Harmful if swallowed 吞食有害
  • H351 Suspected of causing cancer 怀疑致癌
Personal Protective Equipment Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
RTECSYR1400000
Hazard Codes Xn Xn,Xi
TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - guinea pig
DOSE/DURATION           : 37 gm/kg/2Y-C
TOXIC EFFECTS :
   Tumorigenic - neoplastic by RTECS criteria
   Endocrine - thyroid tumors
REFERENCE :
   GROWAH Growth.  (Southern Bio-Research Institute, Florida Southern College,
   Lakeland, FL 33802) V.1-    1937-  Volume(issue)/page/year: 27,305,1963

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - hamster
DOSE/DURATION           : 653 gm/kg/70W-C
TOXIC EFFECTS :
   Tumorigenic - Carcinogenic by RTECS criteria
   Endocrine - thyroid tumors
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 21,952,1968

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 600 gm/kg/73W-C
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Endocrine - tumors
REFERENCE :
   PSEBAA Proceedings of the Society for Experimental Biology and Medicine.
   (Academic Press, Inc., 1 E. First St., Duluth, MN 55802)  V.1-    1903/04-
   Volume(issue)/page/year: 112,365,1963

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 116 mg/kg/11W-I
TOXIC EFFECTS :
   Liver - other changes
REFERENCE :
   AIMDAP Archives of Internal Medicine.  (AMA, 535 N. Dearborn St., Chic

{

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 42857 ug/kg/10D-I
TOXIC EFFECTS :
   Kidney, Ureter, Bladder - changes in tubules (

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 400 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   JPETAB Journal of Pharmacology and Experimental Therapeutics.  (Williams &
   Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-
   Volume(issue)/page/year: 97,478,1949

TYPE OF TEST

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - child
DOSE/DURATION           : 900 mg/kg/60D-I
TOXIC EFFECTS :
   Liver - hepatitis (hepatocellular necrosis), diffuse
   Liver - jaundice, other or unclassified
REFERENCE :
   AIMEAS Annals of Internal Medicine.  (American College of Physicians, 4200
   Pine St., Philadelphia, PA 19104)  V.1-    1927-  Volume(issue)/page/year:
   82,228,1975

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 116 mg/kg/11W-I
TOXIC EFFECTS :
   Liver - other changes
REFERENCE :
   AIMDAP Archives of Internal Medicine.  (AMA, 535 N. Dearborn St., Chicago,
   IL 60610)  V.1-    1908-  Volume(issue)/page/year: 135,319,1975

{hazard_co

TYPE OF TEST            : DNA inhibition
TEST SYSTEM             : Human Lymphocyte
DOSE/DURATION           : 100 mg/L
REFERENCE :
   JCEMAZ Journal of Clinical Endocrinology and Metabolism.  (Williams &
   Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.12-    1952-
   Volume(issue)/page/year: 43,1406,1976

TYPE OF TEST            : Mutation in microorganisms
TEST SYSTEM             : Yeast - Saccharomyces cerevisiae
DOSE/DURATION           : 1 gm/L
REFERENCE :
   CHINAG Chemistry and Industry (London).  (Royal Soc. of Chemistry,
   Distribution Centre, Blackhorse Rd., Letchworth, Herts SG6 1HN, UK)  V.1-
   1923-  Volume(issue)/page/year: (21),847,1980

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Parenteral
SPECIES OBSERVED        : Mammal - species unspecified
DOSE                    : 615 ug/kg
SEX/DURATION            : female 29-32 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - endocrine system
REFERENCE :
   ANREAK Anatomical Record.  (Alan R. Liss, Inc., 41 E. 11th St., New York, NY
   10003)  V.1-    1906/08-  Volume(issue)/page/year: 175,290,1973

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 500 mg/kg
SEX/DURATION            : female 18-22 day(s) after conception
                          lactating female 20 day(s) post-birth
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - endocrine system
   Reproductive - Specific Developmental Abnormalities - urogenital system
   Reproductive - Effects on Newborn - physical
REFERENCE :
   JOENAK Journal of Endocrinology.  (Biochemical Soc. Book Depot, POB 32,
   Commerce Way, Colchester, Essex CO2 8HP, UK)  V.1-    1939-
   Volume(issue)/page/year: 62,213,1974

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE                    : 1092 mg/kg
SEX/DURATION            : female 14-40 week(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - endocrine system
   Reproductive - Effects on Newborn - other neonatal measures or effects
REFERENCE :
   AIMEAS Annals of Internal Medicine.  (American College of Physicians, 4200
   Pine St., Philadelphia, PA 19104)  V.1-    1927-  Volume(issue)/page/year:
   46,145,1957

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROU

TYPE OF TEST            : TDLo - Lowest published toxi

其他信息

  • 图谱信息:丙基硫氧嘧啶(51-52-5)红外图谱(IR2) 丙基硫氧嘧啶(51-52-5)红外图谱(IR1) 丙基硫氧嘧啶(51-52-5)核磁图( 13 CNMR) 丙基硫氧嘧啶(51-52-5)核磁图( 1 HNMR)
  • Sigma Aldrich:51-52-5(sigmaaldrich)
  • 丙基硫氧嘧啶价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2014/06/02 P0533 6-丙基-2-硫代尿嘧啶 6-Propyl-2-thiouracil 25G 160元 2010/06/21 SB00664FA 丙基硫氧嘧啶 2-mercapto-6-propylpyrimidin-4-ol 100 GR 945元 2010/06/21 SB00664EE 丙基硫氧嘧啶 2-mercapto-6-propylpyrimidin-4-ol 50 GR 660元
  • 海关编码:29335995
  • MSDS 信息:2-Mercapto-6-propylpyrimid-4-one(51-52-5).msds
  • 用途二:抗甲状腺药。
  • MOL 文件:51-52-5.mol
  • 用途一:抗甲状腺药,用于对抗甲状腺机能亢进、毒性甲状腺肿或供甲状腺手术前的准备用
  • Hazard Note:Harmful/Irritant
  • Acros Organics:6-丙基-2-硫脲嘧啶 4-Hydroxy-2-mercapto-6-propylpyrimidine, 98%(51-52-5)
  • 丙基硫氧嘧啶价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2011/04/16 P0533 6-丙基-2-硫代尿嘧啶 6-Propyl-2-thiouracil 25G 393元 2010/06/21 SB00664FA 丙基硫氧嘧啶 2-mercapto-6-propylpyrimidin-4-ol 100 GR 945元 2010/06/21 SB00664EE 丙基硫氧嘧啶 2-mercapto-6-propylpyrimidin-4-ol 50 GR 660元
  • 检测方法:HPLC,NMR
  • TCI Shanghai:6-丙基-2-硫代-尿嘧啶 6-Propyl-2-thiouracil,>;99.0%(T)(51-52-5)
  • 极微溶于水、乙醚,微溶于乙醇,可溶于碱性氢氧化物溶液中。

系列性分类


相关产品推荐